Ionis Pharmaceuticals
IONS
390 hedge funds and large institutions have $7.29B invested in Ionis Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 116 increasing their positions, 131 reducing their positions, and 43 closing their positions.
60% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 43
6% more funds holding
Funds holding: 369 → 390 (+21)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% less capital invested
Capital invested by funds: $7.3B → $7.29B (-$9.2M)
0.96% less ownership
Funds ownership: 86.79% → 85.83% (-0.96%)
11% less repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 131
13% less call options, than puts
Call options by funds: $89M | Put options by funds: $103M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$74.1M |
| 2 |
Rockefeller Capital Management
New York
|
+$29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$24.9M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$22.3M |
| 5 |
JP Morgan Chase
New York
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$80M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$60M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$59M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
-$26.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$22.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TIM
426
Tortoise Investment Management
White Plains,
New York
| – | -$2K | -26 | Closed |
|
427
AssetMark Inc
Concord,
California
| – | -$2K | -25 | Closed |
|
|
TCOV
428
Trust Company of Vermont
Brattleboro,
Vermont
| – | -$1K | -16 | Closed |
|
|
PA
429
Procyon Advisors
Shelton,
Connecticut
| – | +$179 | +3 | New |
|
|
AA
430
Argent Advisors
Monroe,
Louisiana
| – | +$477 | +8 | New |
|
IONS Hedge Fund Activity: Q4 2019 in Review
390 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2019, worth a combined $7.29B — down 0.13% from $7.3B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new IONS positions and 43 closed out — a net gain of 26 holders — while 116 added to existing stakes and 131 trimmed.
The largest buyer was BVF Inc, adding an estimated $74.1M. The largest seller was ClearBridge Investments, cutting an estimated $80M.
- 390 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2019, up from 369 in Q3 2019.
- Funds reported $7.29B of Ionis Pharmaceuticals stock for Q4 2019, down 0.13% quarter-over-quarter.
- 69 funds opened new Ionis Pharmaceuticals positions in Q4 2019 and 43 closed out, a net change of +26 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2019 was BVF Inc, an estimated $74.1M added.
- The largest Ionis Pharmaceuticals seller in Q4 2019 was ClearBridge Investments, an estimated $80M sold.
Based on aggregated 13F filings for Q4 2019.